Hypomyelinating Leukodystrophy 9 C4015323
A hereditary disorder causing abnormal myelin formation in the brain, leading to progressive neurological problems. It usually appears in early childhood with symptoms like poor coordination, stiffness, and speech delays. Management is supportive, including physical therapy and medications for symptom control.
Key facts at a glance
- ICD-10
- G40.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Progressive motor impairment
(neurologic)Spasticity
(neurologic)Seizures
(neurologic)Peripheral neuropathy
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Medication management with follow-up
Active treatment with regular monitoring by a healthcare provider is recommended.
Neuroimaging and neurological monitoring
Regular MRI scans to track white matter changes and disease progression, combined with periodic neurological examinations to assess motor function, cognitive status, and developmental milestones in affected individuals.
Comprehensive rehabilitation program
Individualized physical therapy focusing on motor skill development, balance training, and spasticity management to maintain functional mobility and prevent contractures. Therapy intensity adapts as disease progresses.
Additional treatment options
Symptomatic spasticity management
Pharmacological interventions to address spasticity and muscle stiffness, which are common complications affecting quality of life and mobility in leukodystrophy patients.
medicationAdaptive equipment and environmental modifications
Provision of wheelchairs, adaptive utensils, and home modifications to support independence and safety as motor function declines, improving overall quality of life.
lifestyleSupportive care and family counseling
Psychological support for patients and families dealing with progressive neurological disease, including genetic counseling services and connection to support networks.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Hypomyelinating Leukodystrophy 9 C4015323?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Hypomyelinating Leukodystrophy 9 C4015323. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy